Cochlear Limited
Cochlear Limited provides implantable hearing solutions for children and adults worldwide. The company offers cochlear implant systems, sound processor upgrades, bone conduction systems, and other products. It also provides cochlear nucleus systems, including Nucleus sound processors, smart bimodal hearing solution, and Nucleus implants; cochlear Baha systems comprising Baha 6 max sound processor… Read more
Cochlear Limited (CHEOF) - Net Assets
Latest net assets as of June 2025: $1.95 Billion USD
Based on the latest financial reports, Cochlear Limited (CHEOF) has net assets worth $1.95 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.83 Billion) and total liabilities ($874.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.95 Billion |
| % of Total Assets | 69.04% |
| Annual Growth Rate | 17.43% |
| 5-Year Change | 14.61% |
| 10-Year Change | 334.79% |
| Growth Volatility | 20.91 |
Cochlear Limited - Net Assets Trend (1996–2025)
This chart illustrates how Cochlear Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cochlear Limited (1996–2025)
The table below shows the annual net assets of Cochlear Limited from 1996 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $1.95 Billion | +5.97% |
| 2024-06-30 | $1.84 Billion | +5.24% |
| 2023-06-30 | $1.75 Billion | +3.74% |
| 2022-06-30 | $1.69 Billion | -0.94% |
| 2021-06-30 | $1.70 Billion | +21.42% |
| 2020-06-30 | $1.40 Billion | +93.07% |
| 2019-06-30 | $725.90 Million | +18.84% |
| 2018-06-30 | $610.80 Million | +12.35% |
| 2017-06-30 | $543.65 Million | +21.20% |
| 2016-06-30 | $448.56 Million | +26.22% |
| 2015-06-30 | $355.39 Million | +7.95% |
| 2014-06-30 | $329.20 Million | -7.76% |
| 2013-06-30 | $356.91 Million | -7.27% |
| 2012-06-30 | $384.88 Million | -23.53% |
| 2011-06-30 | $503.28 Million | +14.82% |
| 2010-06-30 | $438.31 Million | +20.34% |
| 2009-06-30 | $364.23 Million | +14.06% |
| 2008-06-30 | $319.34 Million | +22.44% |
| 2007-06-30 | $260.81 Million | +24.33% |
| 2006-06-30 | $209.78 Million | +26.47% |
| 2005-06-30 | $165.87 Million | +13.98% |
| 2004-06-30 | $145.53 Million | +21.59% |
| 2003-06-30 | $119.69 Million | +58.70% |
| 2002-06-30 | $75.42 Million | +35.90% |
| 2001-06-30 | $55.49 Million | +29.57% |
| 2000-06-30 | $42.83 Million | +25.78% |
| 1999-06-30 | $34.05 Million | +6.09% |
| 1998-06-30 | $32.09 Million | +37.71% |
| 1997-06-30 | $23.31 Million | +26.28% |
| 1996-06-30 | $18.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cochlear Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 5368.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $777.30 Million | 39.86% |
| Common Stock | $1.18 Billion | 60.30% |
| Other Comprehensive Income | $-3.00 Million | -0.15% |
| Total Equity | $1.95 Billion | 100.00% |
Cochlear Limited Competitors by Market Cap
The table below lists competitors of Cochlear Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Admiral Group plc
PINK:AMIGF
|
$10.33 Billion |
|
Luckin Coffee
PINK:LKNCY
|
$10.34 Billion |
|
YPF S.A. D
BA:YPFD
|
$10.34 Billion |
|
Ally Financial Inc
NYSE:ALLY
|
$10.34 Billion |
|
Grab Holdings Ltd
NASDAQ:GRAB
|
$10.31 Billion |
|
ARC Resources Ltd.
PINK:AETUF
|
$10.30 Billion |
|
AB SKF (publ)
PINK:SKUFF
|
$10.28 Billion |
|
Hua Nan Financial Holdings Co Ltd
TW:2880
|
$10.28 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cochlear Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,840,500,000 to 1,950,300,000, a change of 109,800,000 (6.0%).
- Net income of 388,900,000 contributed positively to equity growth.
- Dividend payments of 278,200,000 reduced retained earnings.
- Share repurchases of 28,300,000 reduced equity.
- New share issuances of 100,000 increased equity.
- Other comprehensive income increased equity by 28,600,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $388.90 Million | +19.94% |
| Dividends Paid | $278.20 Million | -14.26% |
| Share Repurchases | $28.30 Million | -1.45% |
| Share Issuances | $100.00K | +0.01% |
| Other Comprehensive Income | $28.60 Million | +1.47% |
| Other Changes | $-1.30 Million | -0.07% |
| Total Change | $- | 5.97% |
Book Value vs Market Value Analysis
This analysis compares Cochlear Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.33x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 429.54x to 5.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-06-30 | $0.37 | $158.55 | x |
| 1997-06-30 | $0.47 | $158.55 | x |
| 1998-06-30 | $0.64 | $158.55 | x |
| 1999-06-30 | $0.67 | $158.55 | x |
| 2000-06-30 | $0.84 | $158.55 | x |
| 2001-06-30 | $1.07 | $158.55 | x |
| 2002-06-30 | $1.44 | $158.55 | x |
| 2003-06-30 | $2.26 | $158.55 | x |
| 2004-06-30 | $2.58 | $158.55 | x |
| 2005-06-30 | $2.97 | $158.55 | x |
| 2006-06-30 | $3.77 | $158.55 | x |
| 2007-06-30 | $4.69 | $158.55 | x |
| 2008-06-30 | $5.73 | $158.55 | x |
| 2009-06-30 | $6.51 | $158.55 | x |
| 2010-06-30 | $7.75 | $158.55 | x |
| 2011-06-30 | $8.83 | $158.55 | x |
| 2012-06-30 | $6.76 | $158.55 | x |
| 2013-06-30 | $6.26 | $158.55 | x |
| 2014-06-30 | $5.77 | $158.55 | x |
| 2015-06-30 | $6.21 | $158.55 | x |
| 2016-06-30 | $7.84 | $158.55 | x |
| 2017-06-30 | $9.46 | $158.55 | x |
| 2018-06-30 | $10.60 | $158.55 | x |
| 2019-06-30 | $12.58 | $158.55 | x |
| 2020-06-30 | $23.50 | $158.55 | x |
| 2021-06-30 | $25.89 | $158.55 | x |
| 2022-06-30 | $25.63 | $158.55 | x |
| 2023-06-30 | $26.54 | $158.55 | x |
| 2024-06-30 | $28.00 | $158.55 | x |
| 2025-06-30 | $29.72 | $158.55 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cochlear Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.94%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.60%
- • Asset Turnover: 0.83x
- • Equity Multiplier: 1.45x
- Recent ROE (19.94%) is below the historical average (32.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 58.86% | 15.03% | 1.50x | 2.61x | $9.02 Million |
| 1997 | 46.38% | 14.82% | 1.42x | 2.20x | $8.48 Million |
| 1998 | 41.39% | 0.00% | 0.00x | 2.15x | $10.08 Million |
| 1999 | 47.95% | 0.00% | 0.00x | 2.44x | $12.92 Million |
| 2000 | 47.09% | 0.00% | 0.00x | 2.19x | $15.88 Million |
| 2001 | 56.18% | 14.16% | 1.71x | 2.33x | $25.63 Million |
| 2002 | 53.19% | 15.73% | 1.59x | 2.13x | $32.57 Million |
| 2003 | 48.64% | 20.17% | 1.25x | 1.93x | $46.24 Million |
| 2004 | 0.45% | 0.22% | 1.07x | 1.90x | $-13.27 Million |
| 2005 | 0.72% | 0.34% | 0.68x | 3.14x | $-14.94 Million |
| 2006 | 38.56% | 17.70% | 0.83x | 2.63x | $59.28 Million |
| 2007 | 38.39% | 17.90% | 0.96x | 2.25x | $74.05 Million |
| 2008 | 36.08% | 19.15% | 0.99x | 1.90x | $83.30 Million |
| 2009 | 35.84% | 18.79% | 1.02x | 1.87x | $94.12 Million |
| 2010 | 35.40% | 21.11% | 0.98x | 1.72x | $111.32 Million |
| 2011 | 35.79% | 22.25% | 1.09x | 1.47x | $129.79 Million |
| 2012 | 14.76% | 7.29% | 1.11x | 1.83x | $18.32 Million |
| 2013 | 37.14% | 17.61% | 0.98x | 2.14x | $96.87 Million |
| 2014 | 28.47% | 11.64% | 1.02x | 2.40x | $60.79 Million |
| 2015 | 41.04% | 15.76% | 1.07x | 2.45x | $110.30 Million |
| 2016 | 42.12% | 16.71% | 1.18x | 2.13x | $144.07 Million |
| 2017 | 41.13% | 17.83% | 1.10x | 2.09x | $169.25 Million |
| 2018 | 40.24% | 18.02% | 1.18x | 1.89x | $184.72 Million |
| 2019 | 38.12% | 19.39% | 1.03x | 1.90x | $204.11 Million |
| 2020 | -17.00% | -18.04% | 0.51x | 1.84x | $-378.45 Million |
| 2021 | 19.19% | 21.80% | 0.61x | 1.43x | $156.33 Million |
| 2022 | 17.15% | 17.54% | 0.67x | 1.46x | $120.53 Million |
| 2023 | 17.19% | 15.53% | 0.75x | 1.47x | $125.72 Million |
| 2024 | 19.39% | 15.96% | 0.81x | 1.49x | $172.75 Million |
| 2025 | 19.94% | 16.60% | 0.83x | 1.45x | $193.87 Million |
Industry Comparison
This section compares Cochlear Limited's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cochlear Limited (CHEOF) | $1.95 Billion | 58.86% | 0.45x | $10.33 Billion |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |